Indaptus Therapeutics, Inc

Kura Oncology, Inc., based in San Diego, CA, is dedicated to discovering and developing innovative cancer therapeutics aimed at improving patient outcomes and addressing significant unmet needs in oncology. The company focuses on precision medicines and the development of novel therapies designed to selectively target cancer cells, thereby enhancing clinical benefits for patients with various types of cancers, including acute leukemias and head and neck cancer. With a commitment to pioneering new approaches to cancer treatment, Kura collaborates with established standards of care to explore combination therapies that provide patients with a better chance for long-term remissions. Their pipeline includes promising investigational drugs such as Ziftomenib, Tipifarnib, and KO-2806, reflecting their mission to help patients lead longer, healthier lives through cutting-edge science and compassionate care. Generated from the website

Ranir LLC, based in San Diego, CA, is a global self-care company that specializes in providing high-quality oral self-care products for consumers worldwide. Their extensive product portfolio includes items such as toothbrushes, teeth whiteners, dental floss, night guards, and more, available at major retailers across North America. With a commitment to sustainability, quality, and product safety, Ranir LLC also manufactures and markets well-known brands like Plackers and Rembrandt, offering professional-level teeth whitening solutions for customers looking to achieve their brightest smiles from the comfort of their own homes. Generated from the website

Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company based in San Diego, CA, dedicated to developing innovative oral therapies for patients suffering from autoimmune inflammatory and neurodegenerative diseases. Leveraging expertise in medicinal chemistry, structural biology, and immunology, Ventyx aims to create differentiated small molecule therapeutics for conditions with significant unmet medical needs. The company's lead portfolio includes NLRP3 inhibitors such as VTX2735 and VTX3232, both in Phase 2 development for various diseases, alongside candidates for inflammatory bowel disease like tamuzimod and VTX958, which have completed Phase 2 trials. Ventyx is committed to advancing its drug candidates through clinical trials to improve patient outcomes. Generated from the website